This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Relationship between estimated glomerular filtration rate and kidney disease

Authoring team

Relationship between estimated glomerular filtration rate (eGFR) and stages of chronic kidney disease (CKD):

  • Stage 1: Normal GFR; GFR >90 mL/min/1.73 m2 with other evidence of chronic kidney damage*
  • Stage 2: Mild impairment; GFR 60-89 mL/min/1.73 m2 with other evidence of chronic kidney damage*
  • Stage 3: Moderate impairment; GFR 30-59 mL/min/1.73 m2
  • Stage 4: Severe impairment: GFR 15-29 mL/min/1.73 m2
  • Stage 5: Established renal failure (ERF): GFR < 15 mL/min/1.73 m2 or on dialysis

* “other evidence of chronic kidney damage” may be one of the following:

  • persistent microalbuminuria
  • persistent proteinuria
  • persistent haematuria (after exclusion of other causes, e.g. urological disease)
  • structural abnormalities of the kidneys demonstrated on ultrasound scanning or other radiological tests, e.g. polycystic kidney disease, reflux nephropathy
  • biopsy-proven chronic glomerulonephritis (most of these patients will have microalbumuria or proteinuria, and/or haematuria)

Note that patients found to have a GFR of 60-89 mL/min/1.73 m2 without one of these markers should not be considered to have CKD and should not be subjected to further investigation unless there are additional reasons to do so.

Reference:

  1. The Renal Association (May 2006).UK CKD Guidelines
  2. Doctor (June 28th 2005):23.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.